Clinical Trial Results: Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV∆G-ZEBOV-GP Vaccine) [Phase 2]

View source ↗

Summary

Phase 2 trial results assessing the immunogenicity of the rVSV∆G-ZEBOV-GP Ebola vaccine in healthy volunteers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• rVSV∆G-ZEBOV-GP vaccine (recombinant vesicular stomatitis virus vaccine expressing Ebola Zaire GP)

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Healthy Volunteers | Phase 2 | Status: COMPLETED | Results posted: 2026-06-17